MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Horiuchi, Dai, Kusdra, Leonard, Huskey, Noelle E., Chandriani, Sanjay, Lenburg, Marc E., Gonzalez-Angulo, Ana Maria, Creasman, Katelyn J., Bazarov, Alexey V., Smyth, James W., Davis, Sarah E., Yaswen, Paul, Mills, Gordon B., Esserman, Laura J., Goga, Andrei
Format: Artigo
Idioma:Inglês
Publicat: The Rockefeller University Press 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328367/
https://ncbi.nlm.nih.gov/pubmed/22430491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111512
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars